Skip to main content

Table 2 Contribution matrix for any mood episode relapse (the complete contribution matrix is shown on pp. 84–85 of the Appendix in Miura et al. [4])

From: Using the contribution matrix to evaluate complex study limitations in a network meta-analysis: a case study of bipolar maintenance pharmacotherapy review

  Number of comparisons PLB vs LIT PLB vs VPA PLB vs LTG PLB vs IMP PLB vs FLX PLB LIT+IMP PLB vs ARP PLB vs OLZ PLC vs QTP PLB RisLAI PLB vs PAL LIT vs VPA LIT vs CBZ LIT vs LTG LIT vs IMP LIT vs FLX LIT vs LIT+IMP LIT vs LIT+VPA LIT vs LIT+OXC LIT vs OLZ LIT vs QTP VPA vs LIT+VPA VPA vs VPA+ARP LTG vs VPA+LTG LTG vs ARP+LTG IMP vs LIT+IMP OLZ vs RisLAl
Any mood eplaode
 PLB vs LIT 10 27.2 5.3 13.7 2.3   0.2 0.0 4.9 5.7 2.1 0.0 3.1 0.0 13.7 1.8   0.7 2.2 0.0 6.9 5.7 2.2 0.0   0.0 0.5 2.1
 PLB vs VPA 1 14.2 13.0 7.1 1.2   0.1 0.0 2.5 3.0 1.1 0.0 17.0 0.0 7.1 0.9   0.4 12.2 0.0 3.6 3.0 12.2 0.0   0.0 0.3 1.1
 PLB vs LTG 4 9.9 1.9 56.5 0.8   0.1 0.0 1.8 2.0 0.7 0.0 1.1 0.0 17.2 0.6   0.3 0.8 0.0 2.5 2.0 0.8 0.0   0.0 0.2 0.7
 PLB vs IMP 2 14.8 2.9 7.4 8.1   0.5 0.0 2.6 3.1 1.1 0.0 1.7 0.0 7.4 23.9   7.9 1.2 0.0 3.7 3.1 1.2 0.0   0.0 8.4 1.1
 PLB vs LIT+IMP 1 14.3 2.8 7.1 4.3   1.0 0.0 2.5 3.0 1.1 0.0 1.6 0.0 7.1 10.3   20.5 1.2 0.0 3.6 3.0 1.2 0.0   0.0 14.6 1.1
 PLB vs ARP 1 0.0 0.0 0.0 0.0   0.0 100.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   0.0 0.0 0.0 0.0 0.0 0.0 0.0   0.0 0.0 0.0
 PLB vs. OLZ 2 11.5 2.2 5.8 1.0   0.1 0.0 22.5 2.4 9.5 0.0 1.3 0.0 5.8 0.8   0.3 0.9 0.0 23.0 2.4 0.9 0.0   0.0 0.2 9.5
 PLB vs. QTP 2 14.4 2.8 7.2 1.2   0.1 0.0 2.6 23.6 1.1 0.0 1.6 0.0 7.2 0.9   0.4 1.2 0.0 3.7 29.4 1.2 0.0   0.0 0.3 1.1
 PLB vs RisLAI 2 4.6 0.9 2.3 0.4   0.0 0.0 9.0 1.0 49.4 0.0 0.5 0.0 2.3 0.3   0.1 0.4 0.0 9.2 1.0 0.4 0.0   0.0 0.1 18.2
 PLB vs PAL 1 0.0 0.0 0.0 0.0   0.0 0.0 0.0 0.0 0.0 100.0 0.0 0.0 0.0 0.0   0.0 0.0 0.0 0.0 0.0 0.0 0.0   0.0 0.0 0.0
Manio eplaode
 PLB vs LIT 7 39.4 11.6 9.5 0.8   0.4 0.0 0.6 5.9 0.2 0.0 9.4 0.0 9.5 0.7   0.5 2.2 0.0 0.8 5.9 2.2 0.0 0.0 0.0 0.1 0.2
 PLB vs VPA 1 23.2 16.3 5.6 0.5   0.2 0.0 0.3 3.5 0.1 0.0 21.1 0.0 5.6 0.4   0.3 6.4 0.0 0.5 3.5 6.4 0.0 0.0 0.0 0.1 0.1
 PLB vs LTG 3 12.9 3.8 54.3 0.3   0.1 0.0 0.2 1.9 0.1 0.0 3.1 0.0 19.3 0.2   0.2 0.7 0.0 0.3 1.9 0.7 0.0 0.0 0.0 0.0 0.1
 PLB vs IMP 1 20.4 6.0 4.9 2.5   0.6 0.0 0.3 3.1 0.1 0.0 4.9 0.0 4.9 23.8   11.0 1.2 0.0 0 4 3.1 1.2 0.0 0.0 0.0 11.6 0.1
 PLB vs LIT+IMP 1 21.3 6.0 4.9 1.4   1.1 0.0 0.3 3.0 0.1 0.0 4.8 0.0 4.9 11.3   23.3 1.1 0.0 0.4 3.0 1.1 0.0 0.0 0.0 12.7 0.1
 PLB vs ARP 1 0.0 0.0 0.0 0.0   0.0 99.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
 PLB vs OLZ 2 1.2 0.4 0.3 0.0   0.0 0.0 54.7 0.2 20.1 0.0 0.3 0.0 0.3 0.0   0.0 0.1 0.0 2.1 0.2 0.1 0.0 0.0 0.0 0.0 20.1
 PLB vs QTP 2 22.2 6.6 5.4 0.4   0.2 0.0 0.3 15.0 0.1 0.0 5.3 0.0 5.4 0.4   0.3 1.3 0.0 0.4 35.3 1.3 0.0 0.0 0.0 0.1 0.1
 PLB vs RisLAI 2 0.4 0.1 0.1 0.0   0.0 0.0 19.4 0.1 58.5 0.0 0.1 0.0 0.1 0.0   0.0 0.0 0.0 0.8 0.1 0.0 0.0 0.0 0.0 0.0 20.2
 PLB vs PAL 1 0.0 0.0 0.0 0.0   0.0 0.0 0.0 0.0 0.0 100.0 0.0 0.0 0.0 0.0   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Dapreesive eplaode
 PLB vs LIT 8 46.5 2.3 8.5 0.8 2.2 0.4 0.0 4.3 6.7 0.5 0.0 1.1 0.0 8.5 0.6 2.2 0.5 1.2 0.0 4.9 6.7 1.2 0.0 0.0 0.0 0.1 0.5
 PLB vs VPA 1 21.2 9.1 3.9 0.4 1.0 0.2 0.0 2.0 3.0 0.2 0.0 15.5 0.0 3.9 0.3 1.0 0.2 16.3 0.0 2.2 3.0 16.3 0.0 0.0 0.0 0.1 0.2
 PLB vsLTG 3 20.8 1.1 34.3 0.3 1.0 0.2 0.0 1.9 3.0 0.2 0.0 0.5 0.0 2.8.6 0.3 1.0 0.2 0.5 0.0 2..2 3.0 0.5 0.0 0.0 0.0 0.1 0.2
 PLB vs IMP 1 22.0 1.1 4.0 7.3 1.1 1.4 0.0 2.1 3.2 0.3 0.0 0.5 0.0 4.0 23.8 1.1 9.9 0.6 0.0 2.3 3.2 0.6 0.0 0.0 0.0 11.3 0.3
 PLB vs FLX 2 17.0 0.9 3.1 0.3 39.6 0.1 0.0 1.6 2.4 0.2 0.0 0.4 0.0 3.1 0.2 25.6 0.2 0.4 0.0 1.8 2.4 0.4 0.0 0.0 0.0 0.0 0.2
 PLB vs LIT+IMP 1 22.5 1.1 4.1 3.1 1.1 3.2 0.0 2.1 3.2 0.3 0.0 0.6 0.0 4.1 9.1 1.1 25.3 0.6 0.0 2.4 3.2 0.6 0.0 0.0 0.0 12.1 0.3
 PLB vs ARP 1 0.0 0.0 0.0 0.0 0.0 0.0 100.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
 PLB vs OLZ 2 9.8 0.5 1.8 0.2 0.5 0.1 0.0 53.1 1.4 6.6 0.0 0.2 0.0 1.8 0.1 0.5 0.1 0.3 0.0 14.2 1.4 0.3 0.0 0.0 0.0 0.0 6.6
 PLB vs QTP 2 12.9 0.7 2.4 0.6 0.6 0.1 0.0 1.2 57.7 0.1 0.0 0.3 0.0 2.4 0.2 0.6 0.1 0.3 0.0 1.4 18.2 0.3 0.0 0.0 0.0 0.0 0.1
 PLB vsRisLAI 2 2.8 0.1 0.5 0.0 0.1 0.0 0 0 15.1 0.4 56.3 0.0 0.1 0.0 0.5 0.0 0.1 0.0 0.1 0.0 4.0 0.4 0.1 0.0 0.0 0.0 0.0 19.2
 PLB vs PAL 1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 100.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
  1. ARP aripiprazole, CBZ carbamazepine, FLX fluoxetine, IMP imipramine, LIT lithium, LTG lamotrigine, OLZ olanzapine, OXC oxcarbazepine, PAL paliperidone, PLB placebo, QTP quetiapine, RisLAI risperidone long-acting injection, VPA valproate